TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.0900nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: <0.100nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.190nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.320nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.530nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.75nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.960nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Rattus norvegicus)
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of PDGFR-beta driven proliferation of rat A10 cells after 68 hrs in presence of rat recombinant PDGF-BB by cell titer-glo luminescence ass...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Rattus norvegicus)
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 2.70nMAssay Description:Inhibition of PDGFR-beta driven proliferation of rat A10 cells after 68 hrs in presence of rat recombinant PDGF-BB by cell titer-glo luminescence ass...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair